Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

AZD5305 hADME en pacientes con neoplasias malignas sólidas avanzadas (AZD5305)

9 de noviembre de 2026 actualizado por: AstraZeneca

Un estudio abierto de fase I para evaluar la biodisponibilidad absoluta de saruparib (AZD5305) y la absorción, distribución, metabolismo y excreción (ADME) de [14C] -Saruparib ([14C]-AZD5305) en pacientes con neoplasias malignas sólidas avanzadas

This Phase I, open-label study aims to study to absolute bioavailability of Saruparib (AZD5305) and the absorption, distribution, metabolism and excretion (ADME) of [14C]-Saruparib in patients with advanced solid malignancies.

This will be done on an inpatient basis in 2 parts (single-dose oral administration with radiolabeled microtracer in Part A, single-dose IV radiolabeled administration in Part B) during which samples will be obtained of plasma, urine, feces and vomitus (where applicable).

Descripción general del estudio

Descripción detallada

This is an open-label, 2-part study in participants with advanced solid malignancies and will be conducted at multiple study sites.

Participants will be assessed for study eligibility prior to admission to the study site during a 28-day screening period. Participants will take part in both Parts A and B of the study.

Part A will assess the absolute bioavailability and evaluate the PK parameters of oral Saruparib and a radiolabelled IV microdose of [14C]-Saruparib

Participants will be admitted to the study site pre-dose of Part A and will remain resident at the study site for PK sampling and safety assessments.

A washout period will be observed between doses of Saruparib in Parts A and B.

Part B will assess the ADME of oral [14C]-Saruparib. Participants will be readmitted to the study site for Part B and will remain resident at the study site for excreta (urine, faeces, and any vomitus) collections, PK sampling, and safety assessments. Participants may be discharged from the study site prior to the last indicated day if both the following discharge criteria are met:

  1. ≥ 90% mass balance recovery, and
  2. < 1% of the total radioactive dose is recovered in combined excreta (urine and faeces) in 2 consecutive 24-hour periods.

Participants will return to the study site for a Follow-up Visit after the last dose of Saruparib which will include routine safety assessments. After the completion of Parts A and B, and following the Follow-up Visit, participants may be allowed further access to Saruparib.

Additional safety data collection will be conducted.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

8

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Liverpool, Reino Unido, L7 8YA
        • Reclutamiento
        • Research Site
      • Manchester, Reino Unido, M20 4BX
        • Reclutamiento
        • Research Site

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Male or female ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place), at the time of signing the ICF.
  2. Histologically or cytologically documented, locally advanced or metastatic solid tumour, excluding lymphoma, for which standard therapy does not exist or has proven ineffective or intolerable.
  3. ECOG performance status of 0 or 1 with no deterioration over the 2 weeks prior to dosing.
  4. Predicted life expectancy ≥ 12 weeks.
  5. Adequate organ and marrow function as defined in the protocol
  6. Willingness and ability to comply with study and follow-up procedures.
  7. Able and willing to stay in hospital for specified residential periods following administration of Saruparib/[14C]-Saruparib
  8. Regular bowel movements
  9. Body weight within normal range specified in protocol
  10. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies Reproduction
  11. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in the protocol

Exclusion Criteria:

  1. Participants with a history of MDS/AML or with features suggestive of MDS/AML (as determined by prior diagnostic investigation). Specific screening for MDS/AML is not required.
  2. Participants with any known predisposition to bleeding
  3. Any history of persisting severe cytopenia due to any cause
  4. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of Saruparib.
  5. History of another primary malignancy, with some exceptions
  6. Persistent toxicities (CTCAE Grade ≥ 2), excluding alopecia and peripheral neuropathy, caused by previous anticancer therapy.
  7. Spinal cord compression or brain metastases for at least 4 weeks prior to start of study intervention unless asymptomatic and stable
  8. Abnormal cardiac function exclusions or cardiovascular disease
  9. History of arrhythmia
  10. Active HBV (positive HBsAg result) or HCV.
  11. Evidence of active and uncontrolled HIV infection.
  12. Active tuberculosis infection
  13. Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.
  14. As judged by the investigator, any other evidence of diseases (such as severe or uncontrolled systemic diseases or active uncontrolled infections which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or would jeopardise compliance with the protocol.
  15. Any prior treatment with Saruparib.
  16. Other anticancer therapy (chemotherapy, immunotherapy, hormonal anticancer therapy, radiotherapy [except for palliative local radiotherapy]), biological therapy or other novel agent is not permitted until the last PK sampling is completed.
  17. Palliative radiotherapy with a limited field of radiation within 2 weeks or with wide field of radiation or to more than 30% of the bone marrow within 4 weeks before the first dose of study intervention
  18. Concomitant use of medications or herbal supplements known to be CYP3A4 strong inhibitors or inducers
  19. Concomitant use of drugs that are known to prolong or shorten QT and have a known risk of Torsades de Pointes
  20. Participants who have participated in another absorption, distribution, metabolism, and excretion study within 1 year prior to screening.
  21. Participation in another clinical study with a study intervention administered in the last 1 month or 5 half-lives prior to dosing, whichever is longer.
  22. Participants with a known hypersensitivity to Saruparib or any of the excipients of the product.
  23. Participants who have been administered any amount of a [14C]-labelled compound within the last 12 months.
  24. Use of tobacco- or nicotine-containing products or alcohol may be exclusionary
  25. Poor peripheral venous access (venous access via a port will be permitted).
  26. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  27. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
  28. Previous enrolment in the present study.
  29. For female participants only: currently pregnant (confirmed with positive pregnancy test) or planning to become pregnant, breast-feeding, or intending to donate/retrieve ova before 6 months after the last dose of Saruparib.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Ciencia básica
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Primary Treatment Arm - AZD5305

Part A will assess absolute bioavailability via oral administration of Saruparib (AZD5305) and IV [14C]-saruparib microtracer.

Part B will assess ADME via IV [14C]-saruparib administration

PARP-inhibitor

Otros nombres:
  • Saruparib

IV radiolabeled microtracer

Otros nombres:
  • Microtrazador IV [14C]-Saruparib

IV radiolabeled PARP inhibitor

Otros nombres:
  • [14C]-Saruparib IV (dosis terapéutica)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Absolute bioavailability (F) of Saruparib
Periodo de tiempo: Day 4

Absolute bioavailability (F) of Saruparib

Day 4
Total radioactivity recovery in urine and faeces
Periodo de tiempo: Day 8

Total radioactivity recovery in urine and faeces

Day 8
Pharmacokinetics of Saruparib(Part B)
Periodo de tiempo: Day 8

AUCinf

Day 8
PK parameters characterized by AUCinf
Periodo de tiempo: Day 4

AUCinf

Day 4
Ratio of AUCinf of plasma Saruparib relative to AUCinf of metabolite
Periodo de tiempo: Day 4

Ratio of AUCinf of plasma Saruparib relative to AUCinf of metabolite

Day 4
Mass balance parameters as characterized by amount excreted and cumulative amount excreted in urine, faeces and total (urine and faeces combined)
Periodo de tiempo: Day 8

Cumulative amount excreted in urine, faeces and total (urine and faeces combined)

Day 8
Amount excreted and cumulative amount excreted in urine, faeces and total (urine and faeces combined) expressed as a percentage of the administered dose
Periodo de tiempo: Day 8

Amount excreted and cumulative amount excreted in urine, faeces and total (urine and faeces combined) expressed as a percentage of the administered dose.

Day 8
Pharmacokinetics of Saruparib(Part B)
Periodo de tiempo: Day 8

AUClast

Day 8
Pharmacokinetics of Saruparib(Part B)
Periodo de tiempo: Day 8

Cmax

Day 8
Pharmacokinetics of Saruparib(Part B)
Periodo de tiempo: Day 8

tmax

Day 8
Pharmacokinetics of Saruparib(Part B)
Periodo de tiempo: Day 8

t1/2(lambda)z

Day 8
Pharmacokinetics of Saruparib(Part B)
Periodo de tiempo: Day 8

Ratio of AUCinf of plasma Saruparib relative to AUCinf of plasma total radioactivity

Day 8
Pharmacokinetics of Saruparib(Part B)
Periodo de tiempo: Day 8

Ratio of AUCinf of whole blood total radioactivity relative to AUCinf of plasma total radioactivity

Day 8
PK parameters characterized by AUClast
Periodo de tiempo: Day 4

AUClast

Day 4
PK parameters characterized by Cmax
Periodo de tiempo: Day 4

Cmax

Day 4
PK parameters characterized by tmax
Periodo de tiempo: Day 4

tmax

Day 4
PK parameters characterized by t1/2(lambda)z
Periodo de tiempo: Day 4

t1/2(lambda)z

Day 4

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Metabolic profiling of a single oral dose of [14C]-Saruparib (Part B)
Periodo de tiempo: Day 8

Determining mass balance parameters following oral administration of a therapeutic dose containing 20uCi of 14C-AZD5305 followed by metabolite profiling and identification in plasma, urine, and feces to quantify the 14C-AZD5305 related material in each matrix to satisfy MIST considerations.

Day 8
Characterize the safety of Saruparib in participants with advanced solid malignancies by incidence and severity of AEs, laboratory abnormalities, 12-lead ECG abnormalities, vital signs abnormalities, physical examination findings
Periodo de tiempo: Day 14

incidence and severity of AEs, -incidence of laboratory abnormalities (based on hematology, clinical chemistry, and urinalysis test results), -12-lead ECG abnormalities, vital signs abnormalities, physical examination findings

Day 14

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

2 de abril de 2025

Finalización primaria (Estimado)

31 de diciembre de 2026

Finalización del estudio (Estimado)

8 de febrero de 2027

Fechas de registro del estudio

Enviado por primera vez

30 de julio de 2024

Primero enviado que cumplió con los criterios de control de calidad

27 de noviembre de 2024

Publicado por primera vez (Actual)

3 de diciembre de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

9 de noviembre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir